DGX Stock Recent News
DGX LATEST HEADLINES
SECAUCUS, N.J. , Aug. 5, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced the completion of its previously announced acquisition of select clinical testing assets of Fresenius Medical Care's wholly owned Spectra Laboratories, a leading provider of renal-specific laboratory testing services in the United States.
New test utilizes technology based on PacBio's PureTarget sequencing method to uncover genetic causes of disease BOSTON , July 29, 2025 /PRNewswire/ -- Athena Diagnostics, the specialty neurology business of Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced a new laboratory test service intended to provide insights into genetic causes of ataxia, a group of progressive, degenerative neurological disorders that affect movement or coordination. The new service is a laboratory developed test that identifies sequences of DNA that repeat many times across a long stretch of the genome.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Diagnostic testing and information services provider Quest Diagnostics (DGX 7.04%) reported fiscal 2025 second-quarter results on Tuesday, July 22, that topped analysts' consensus expectations. Q2 revenue hit $2.76 billion and adjusted earnings per share (EPS) came in at $2.62.
Quest Diagnostics (DGX 7.16%) reported its second-quarter 2025 results on July 22, achieving consolidated revenue of $2.76 billion (up 15.2% year over year), organic revenue growth of 5.2%, while adjusted EPS rose 11.5% year over year to $2.62. Management raised full-year revenue guidance to $10.8 billion to $10.92 billion and adjusted EPS to $9.63 to $9.83, citing sustained demand for advanced diagnostics, the integration of last year's LifeLabs acquisition, and scale-driven productivity gains.
Quest Diagnostics Inc. DGX delivered a robust second quarter in 2025, exceeding analyst expectations with strong sales and earnings growth, prompting an upward revision to its full-year guidance.
Quest Diagnostics Incorporated (NYSE:DGX ) Q2 2025 Earnings Conference Call July 22, 2025 8:30 AM ET Company Participants James E. Davis - Chairman, CEO & President Sam A.
DGX tops Q2 estimates with 15.2% revenue growth and a strong EPS beat, lifting the stock 3.2% in pre-market trading.
Quest Diagnostics (DGX) came out with quarterly earnings of $2.62 per share, beating the Zacks Consensus Estimate of $2.57 per share. This compares to earnings of $2.35 per share a year ago.
Laboratory operator Quest Diagnostics raised its 2025 profit and revenue forecasts on Tuesday, banking on robust demand for its diagnostic tests, sending the company's shares up over 3% in premarket trade.